Carisma Therapeutics Stock (NASDAQ:CARM)
Previous Close
$0.88
52W Range
$0.80 - $3.16
50D Avg
$0.98
200D Avg
$1.44
Market Cap
$36.20M
Avg Vol (3M)
$145.29K
Beta
-
Div Yield
-
CARM Company Profile
Carisma Therapeutics, Inc., a biopharmaceutical company, develops chimeric antigen receptors (CAR) macrophages for the treatment of solid tumors. Its solutions are used to play a crucial role in the innate and adaptive immune response, and technology leverages advances in macrophage biology, chimeric antigen receptor engineering, and adoptive cellular therapy for the treatment of human diseases. Carisma Therapeutics, Inc. has a strategic collaboration agreement with Moderna Inc. Carisma Therapeutics, Inc. was formerly known as CARMA Therapeutics Inc. and changed its name to Carisma Therapeutics, Inc. in May 2017. The company was incorporated in 2016 and is based in Philadelphia, Pennsylvania.
CARM Performance
Peer Comparison
| Ticker | Company |
|---|---|
| ZVSA | ZyVersa Therapeutics, Inc. |
| CNSP | CNS Pharmaceuticals, Inc. |
| VECT | VectivBio Holding AG |
| AVRO | AVROBIO, Inc. |
| EFTR | eFFECTOR Therapeutics, Inc. |
| IMMX | Immix Biopharma, Inc. |
| CYTO | Altamira Therapeutics Ltd. |
| HEPA | Hepion Pharmaceuticals, Inc. |
| ZURA | Zura Bio Limited |
| ENVB | Enveric Biosciences, Inc. |
| PALI | Palisade Bio, Inc. |